Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00314743 · ClinicalTrials.gov registry record · Early Phase 1
Efficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell Transplantation
A Early Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 48
- Enrollment target
NCT00314743 is a Early Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 48 participants.
The verdict
NCT00314743, a Early Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy of aprepitant in preventing acute and delayed chemotherapy induced nausea and vomiting when administered in combination with intravenous or oral ondansetron and intravenous or oral dexamethasone in the autologous transplant setting.
Interventions
- DRUG Dexamethasone
- DRUG Ondansetron
- DRUG Aprepitant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2005-10 |
| Est. Completion | 2008-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00314743
The ClinicalTrials.gov registry entry for NCT00314743 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT00314743 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00314743 about?
NCT00314743 is a clinical study titled "Efficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell Transplantation". The purpose of this study is to determine the efficacy of aprepitant in preventing acute and delayed chemotherapy induced nausea and vomiting when administered in combination with intravenous or oral ondansetron and intravenous or oral dexamethasone in the autologous transplant setting.
What is the current status of trial NCT00314743?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 48 participants. The study started on 2005-10. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00314743?
The interventions under investigation include: Dexamethasone (DRUG), Ondansetron (DRUG), Aprepitant (DRUG).
Who is sponsoring clinical trial NCT00314743?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.